16
Participants
Start Date
April 22, 2019
Primary Completion Date
May 18, 2020
Study Completion Date
July 31, 2020
BBT-401-1S first and then Placebo
Total 16 week treatment period: The subject takes BBT-401-1S, QD for the first 12 weeks, then placebo for the last 4 weeks.
Placebo first and then BBT-401-1S
Total 16 week treatment period: The subject takes the placebo, QD for the first 8 weeks, then BBT-401-1S for the last 8 weeks.
Site 04, Rockville
Site 02, Monroe
Site 12, Pembroke Pines
Site 11, Boca Raton
Site 08, Chattanooga
Site 10, Ann Arbor
Site 13, McAllen
Site 05, Austin
Site 01, Ventura
Site 03, Sacramento
Site 09, Seattle
Lead Sponsor
Collaborators (1)
KCRN Research, LLC
INDUSTRY
Bridge Biotherapeutics, Inc.
INDUSTRY